Loading…
← CockpitCompetitor Analysis › ELVN Enliven Therapeutics, Inc.Open in the cockpit ↗

Enliven Therapeutics, Inc.ELVNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops small-molecule kinase inhibitors for cancer, including a next-generation drug for chronic myeloid leukemia.

Momentum neutral 48
Mkt cap
$3.30B
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$64.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.8%
Hurdle
n/a
no reverse DCF
Next earnings
120 days
18 Mar 2027
Close · USD$44.89
1D-4.2%
1W-12.3%
1M+8.8%
3M-23.8%
6M+7.2%
YTD+191.5%
1Y+106.3%
ATR %5.0%
Beta1.12
52w lowhigh28.0% off high

What Enliven Therapeutics does

Develops small-molecule kinase inhibitors for cancer, including a next-generation drug for chronic myeloid leukemia.

Has no approved product, so spending is funded by selling shares, and any income would come from selling an approved drug or from a partnership. Cash runway and trial results decide how easily it can raise more.

Products and services

  • ELVN-001 (BCR-ABL inhibitor, CML)
  • ELVN-002 (HER2 inhibitor)

Customers

  • Oncologists/cancer centers (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Kinase inhibitor oncology

What could go right

  • Clinical data readouts vs standard of care
  • Potential accelerated approval pathway

What could go wrong

  • Competitive CML treatment landscape
  • Clinical trial failure risk

Moat: none (IP / patents). Clinical-stage biotech targeting validated pathways with differentiated molecules, but no approved products.

Headquarters: Boulder, Colorado, US · Founded: 2020 · Employees: 60

Named competitors

Enliven Therapeutics at a glance

Size Enliven Therapeutics (ELVN) is a United States Health Care company (Biotechnology) with a market value of $3.30B, the 1474th largest of 3,085 United States companies the cockpit tracks. Shares closed at $44.89 on 18 Nov 2026.

Performance Over six months the shares gained 7.2%, against +1.1% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.

Short interest Short interest is 14.0% of the free float (30 Oct 2026).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026ELVN 106Peer median 101
Six months, rebased to 100: Enliven Therapeutics against the median of its 20 peers (local-currency closes).

Enliven Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$80,000-$263,000-$317,000-$297,000-$215,000
EBITDA-$135M-$119M-$104M-$83.2M-$38.6M
Net income-$113M-$104M-$89.0M-$71.6M-$37.7M
Free cash flow-$66.4M-$70.5M-$73.2M-$61.4M-$32.7M
Capital expenditure$193,000$158,000$44,000$149,000$612,000
Total debt$1.31M$399,000$0$335,000$323,000

Quarterly statements and history in the cockpit →

Enliven Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%6919002007VIRPIOVA600161XERSIRONABCLADMATLXRLAY603127DNLITNGXRUBICON2228BAVACRSP9688ELVN6-month return →1-month return →
Up and to the right = strong over both horizons. Enliven Therapeutics is the large dot.

Enliven Therapeutics competitors and peer comparison

Head to head with its named competitors (ELVN vs NOVN.SW vs PBYI vs 6855.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Enliven Therapeutics ELVN$3.30B+7%n/an/an/an/a
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Puma Biotechnology PBYI$373M+3%+9%11%1.2×0.1%
Ascentage Pharma Group International 6855.HK$1.18B-34%+70%-220%13.2×n/a

How Enliven Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Enliven Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureELVNPeer medianRank in peer set
1-month return+8.8%-5.6%4th highest of 21
6-month return+7.2%+1.1%10th highest of 21
Distance from 52-week high-28.0%-31.6%10th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%11.8×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%2.6×-4.3%+27.4%
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%5.4×n/an/a

Questions

Who are Enliven Therapeutics's main competitors?
Named competitors: Novartis (Scemblix) (NOVN.SW), Puma Biotechnology (PBYI), Terns Pharmaceuticals (private or unlisted), Ascentage Pharma (6855.HK). The cockpit's measured peer set (industry) also includes Caliway Biopharmaceuticals (6919.TW), Hualan Biological Engineering (002007.SZ), Virbac (VIRP.PA), Iovance Biotherapeutics (IOVA), Beijing Tiantan Biological Products (600161.SS), Xeris Biopharma (XERS).
How has Enliven Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +7.2% against +1.1% for the median peer; over one year +106.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.